27.07.2016 - In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.
Researchers are among those most concerned with the impact the upcoming Brexit will have on their work, and on cross-border scientific collaborations in particular. Last week, seven UK academies published a statement on research and innovation after the EU Referendum, saying: “The result of the EU Referendum presents a challenge to maintaining this excellence. The current uncertainty is having immediate implications and raises many questions.” Sir Venki Ramakrishnan, president of the UK’s Royal Society, now told BBC Newsnight in an interview that the UK government needs to “nip post-Brexit uncertainty in the bud”.
“We’re hearing about UK researchers being excluded from collaborations because their other EU collaborators don't want to take on a UK-based researcher because they don't know what their status will be,” said Ramakrishnan. “Of course, this isn't strictly speaking legal because we are still part of the EU. But you can't police this. If somebody doesn't want to take on a British researcher because they think it's too risky, they simply won't.”
To relieve the doubt, he continued, “the UK could simply say if there are UK-based researchers who apply for EU funding now, then we will underwrite that funding until the end of the grant, regardless of what happens with negotiations. That wouldn't cost a lot of money, but it would certainly resolve this uncertainty about their status.”
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
JANUS® G3 Automation Workstations deliver real-time and future adaptability in throughput, capacity, and dynamic volume range from 0.5 μl to 5000 μl for consistent and reproducible sample preparation more